POZ October/November 2019
POZ October/November 2019
In every issue, you’ll find the hottest topics of interest to our readers along with cutting-edge health information.
Also Available On:
Features
Yearning to Breathe Free
Understanding Immigration and HIV
25 Years of Contributors
POZ writers and artists have thrived at the magical intersection of lived experience and boundless talent.
Indetectable equivale a Intransmisible
Consejos para comunicar
Editor’s Letter
What’s Going On
Our cover story explores how HIV intersects with immigration and affects everyone from asylum seekers to longtime immigrants.
POZ Q+A
Poetic Justice
Lambda Literary speaks with Emanuel Xavier about the club scene, HIV/AIDS and the reissue of his cult novel.
POZ Planet
Prevention Power!
Updates on U=U, PrEP, harm reduction and more
POZ AT 25 — October/November
A look at fall issues from the POZ archives
Everyday
Everyday — October/November 2019
Here are some important dates in AIDS history.
Voices
Missing the Mark
Christine Soyong Harley, CEO of the U.S. Sexuality Information and Education Council, urges schools to address HIV.
Nice AF
Tony Taylor, a project manager at Building Healthy Online Communities, urges kindness.
Spotlight
HIV Border Crisis
Advocates respond to the reports that a father, who is living with HIV, was permanently separated from his daughters after entering the U.S.
Care And Treatment
Very Early HIV Treatment Benefits
A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.
Fostemsavir Can Best Drug-Resistant HIV
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
Islatravir Shows Double Potential
Merck’s experimental HIV drug proves effective and well tolerated
Pharmacists Can Oversee Hep C Treatment
Pharmacist-driven hep C treatment sees good cure rates
Research Notes
Prevention: Vaccine Trial
The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.
Treatment: Capsid Inhibitor
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
Cure: Mouse Gene Edit
CRISPR gene editing eliminates HIV in mice
Concerns: High Anxiety
A high proportion of people with HIV suffer from anxiety, which is associated with lower rates of HIV treatment and adherence to treatment.
Heroes
Moving Mountains
Oscar Lopez advocates for Latinos living with HIV.
Digital Edition
POZ October/November 2019
Read the digital edition!
